NASDAQ: VKTXViking Therapeutics Inc Stock
$68.86+3.79 (+5.82%)
Updated Apr 25, 2024
VKTX Price
$68.86
Fair Value Price
$0.58
Market Cap
$7.59B
52 Week Low
$8.28
52 Week High
$99.41
P/E
-74.04x
P/B
8.13x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$93.72M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.04
Operating Cash Flow
-$55M
Beta
1.09
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
VKTX Overview
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how VKTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VKTX ($68.86) is overvalued by 11,874.22% relative to our estimate of its Fair Value price of $0.58 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
VKTX ($68.86) is not significantly undervalued (11,874.22%) relative to our estimate of its Fair Value price of $0.58 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
VKTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more VKTX due diligence checks available for Premium users.
Be the first to know about important VKTX news, forecast changes, insider trades & much more!
VKTX News
Valuation
VKTX fair value
Fair Value of VKTX stock based on Discounted Cash Flow (DCF)
Price
$68.86
Fair Value
$0.58
Overvalued by
11,874.22%
VKTX ($68.86) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
VKTX ($68.86) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
VKTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
VKTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-74.04x
Industry
15.41x
Market
40.97x
VKTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
8.13x
Industry
5.8x
VKTX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
VKTX's financial health
Profit margin
Revenue
$0.0
Net Income
-$27.4M
Profit Margin
0%
VKTX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$967.5M
Liabilities
$33.6M
Debt to equity
0.04
VKTX's short-term assets ($966.34M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VKTX's short-term assets ($966.34M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VKTX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
VKTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.1M
Investing
-$459.8M
Financing
$606.0M
VKTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
VKTX vs Biotech Stocks
Viking Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.